Powered by Topple

MSNBC’s Chris Hayes scolded for ‘misinformation’ trying to discredit life-saving monoclonal antibodies

Powered by Topple

Left-wing MSNBC host Chris Hayes was ridiculed mercilessly on Sunday after he claimed that monoclonal antibody treatments, used in COVID-19 cases, cost about $2,000 per treatment.

“The monoclonal antibody treatment is developed and sold by big pharma and costs $2000 a pop. The vaccine is free,” the host noted on Twitter in response to former Rep. Allen West, R-Fla., who had shared his and his wife’s experience in getting the treatments for COVID-19 symptoms they have been experiencing.

“I can attest that, after this experience, I am even more dedicated to fighting against vaccine mandates,” West had previously written. “Instead of enriching the pockets of Big Pharma and corrupt bureaucrats and politicians, we should be advocating the monoclonal antibody infusion therapy.”

In fact, according to a recent Washington Post story, monoclonal antibody treatments “are free and effective” against the virus, “but few people are getting them.”

“Monoclonal antibodies are free to patients and there have been almost no side effects. They are accessible on an outpatient basis, via a single infusion or four injections. Hospitals, urgent-care centers and even private doctors are authorized to dispense them,” the paper reported in August.

Critics quickly corrected Hayes and accused the host of spreading disinformation, while actually noting that taxpayers and the government are footing the bill for the treatments as well as the three approved COVID-19 vaccines.

“This deadly disinformation is designed to scare sick people away from monoclonal centers in Florida. Which cost the patient nothing. Chris Hayes is trying to get covid infected patients killed,” one of them noted.

Another said that Hayes’ misinformation could cause some people not to seek out the highly effective treatment.

The Post’s August story noted that the White House COVID-19 Response Team reported at the time that some 600,000 people have gotten monoclonal antibody treatments since the government approved separate versions developed by pharma companies Regeneron and Eli Lilly in November.

Distribution of the latter product has since been discontinued, however, “because it is ineffective against some variants,” the Post added.

“We have a long way to go on how do we reach the general public where they are,” Erin McCreary, director of stewardship innovation at the University of Pittsburgh Medical Center, told the paper. Her facility had treated more than 3,400 patients with the two drugs since Dec. 9 at the time the story was published.

“It is absolutely the standard of care for covid-19. It is my hope that clinics know that,” she added.

Jon Dougherty

Comments

Latest Articles